$152.640
-2.045 (-1.34%)收盤時
RVTY 資訊
RVTY 事件
Everpure Stock Rises $20.86 to $130.51
Notable gainers among liquid option names this morning include Everpure, Inc (P) $130.51 +20.86, Charles River (CRL) $293.77 +16.44, Kroger (KR) $59.45 +1.80, PerkinElmer Inc (RVTY) $146.41 +4.30, and Ralph Lauren (RL) $347.50 +10.03.
Revvity Launches GSP T1D 3plex Detection Kit
Revvity announced the launch of the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic ketoacidosis episode. Using capillary dried blood spots for simple, scalable sample collection, the 3-plex assay is processed on Revvity's GSP instrument, a high-throughput, trusted platform in newborn screening. This end-to-end workflow, which includes reagents, instrumentation, and software, can detect at-risk individuals months or years before symptoms, enabling early intervention and disease-modifying treatment.
Skyworks and Others See Notable Stock Gains
Notable gainers among liquid option names this morning include Skyworks (SWKS) $87.45 +8.19, Dell Technologies (DELL) $563.85 +29.57, PerkinElmer Inc (RVTY) $134.49 +6.00, Qualcomm (QCOM) $188.44 +8.28, and Coherent (COHR) $275.80 +9.30.
Revvity Acquires French Biotech Company HCD
Revvity announced it has entered into a definitive agreement to acquire Human Cell Design, or HCD, a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 and is subject to customary closing conditions, including required regulatory approvals. Additional terms of the transaction were not disclosed. HCD's flagship EndoC-betaH5 human pancreatic beta cell model is designed to provide researchers with a human-relevant model for studying beta cell physiology and function across diabetes and obesity research. HCD also offers specialized media and reagents, preclinical research, and its proprietary NatLine cell-line development platform, which supports the development of functionally consistent human cell models.
Company to Divest Immunodiagnostics Business in China
The company recently entered into a definitive agreement to divest its Immunodiagnostics business in China, which represented approximately 6% of the company's total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The company is providing second quarter 2026 financial results on a reported and pro forma basis; forward-looking guidance is provided on a pro forma basis only and excludes China IDX.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。